Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News United Therapeutics Corp UTHR

Healthcare Biotechnology
United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended... see more

Recent & Breaking News (NDAQ:UTHR)

United Therapeutics to Present New Tyvaso® Clinical and Treprostinil Real-World Data at CHEST Annual Meeting 2020

PR Newswire October 15, 2020

CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for Transplant

PR Newswire September 21, 2020

United Therapeutics Corporation to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

PR Newswire September 16, 2020

United Therapeutics Corporation Appoints Linda Maxwell to Its Board of Directors

PR Newswire September 11, 2020

United Therapeutics Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Tyvaso® For Pulmonary Hypertension Associated With Interstitial Lung Disease

PR Newswire August 17, 2020

United Therapeutics Corporation to Present at the Wedbush PacGrow Healthcare Virtual Conference

PR Newswire August 5, 2020

United Therapeutics Corporation Reports Second Quarter 2020 Financial Results

PR Newswire July 29, 2020

United Therapeutics Corporation Asserts New Tyvaso Patent Against Liquidia

PR Newswire July 23, 2020

United Therapeutics Corporation To Report Second Quarter 2020 Financial Results Before The Market Opens On Wednesday, July 29, 2020

PR Newswire July 22, 2020

United Therapeutics Announces Increase Data Presentation at an American Thoracic Society Virtual Session

PR Newswire June 17, 2020

United Therapeutics Corporation Files Lawsuit Against Liquidia For Infringement Of Tyvaso Patents

PR Newswire June 5, 2020

United Therapeutics Corporation to Present at the Jefferies Virtual Health Care Conference

PR Newswire May 26, 2020

United Therapeutics Corporation To Present At The BofA Securities Virtual Health Care Conference 2020

PR Newswire May 6, 2020

United Therapeutics Corporation Reports First Quarter 2020 Financial Results

PR Newswire April 29, 2020

United Therapeutics Announces Additional Results From FREEDOM-EV Study Showing The Hemodynamic And Risk Status Reduction Benefits Of Orenitram Treatment In Patients With Pulmonary Arterial Hypertension

PR Newswire April 23, 2020

United Therapeutics Corporation to Report First Quarter 2020 Financial Results Before the Market Opens on Wednesday, April 29, 2020

PR Newswire April 22, 2020

Celularity Expands Strategic Collaboration with United Therapeutics Corporation to COVID-19 Infection and Acute Respiratory Distress Syndrome

PR Newswire April 9, 2020

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2019 Financial Results

PR Newswire February 26, 2020

United Therapeutics Corporation To Present At The 40th Annual Cowen And Company Healthcare Conference

PR Newswire February 25, 2020

United Therapeutics and DEKA Announce Additional FDA Clearance Related to the Unity Subcutaneous Delivery System for Remodulin®

PR Newswire February 24, 2020